1. Home
  2. NRO vs ELDN Comparison

NRO vs ELDN Comparison

Compare NRO & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neuberger Berman Real Estate Securities Income Fund Inc.

NRO

Neuberger Berman Real Estate Securities Income Fund Inc.

N/A

Current Price

$2.70

Market Cap

186.3M

Sector

Finance

ML Signal

N/A

Logo Eledon Pharmaceuticals Inc.

ELDN

Eledon Pharmaceuticals Inc.

N/A

Current Price

$2.65

Market Cap

219.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NRO
ELDN
Founded
N/A
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
186.3M
219.4M
IPO Year
2003
2014

Fundamental Metrics

Financial Performance
Metric
NRO
ELDN
Price
$2.70
$2.65
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $9.00
AVG Volume (30 Days)
234.5K
★ 874.3K
Earning Date
01-01-0001
11-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 30.67
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.48
$1.35
52 Week High
$3.16
$4.49

Technical Indicators

Market Signals
Indicator
NRO
ELDN
Relative Strength Index (RSI) 59.38 52.52
Support Level $2.49 $2.63
Resistance Level $3.07 $3.19
Average True Range (ATR) 0.04 0.23
MACD 0.03 0.04
Stochastic Oscillator 78.00 45.89

Price Performance

Historical Comparison
NRO
ELDN

About NRO Neuberger Berman Real Estate Securities Income Fund Inc.

NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.

Share on Social Networks: